Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M54,987Revenue (TTM) $M4,979Net Margin (%)19.3Altman Z-Score13.2
Enterprise Value $M54,388EPS (TTM) $8.3Operating Margin %28.8Piotroski F-Score4
P/E(ttm)62.3Beneish M-Score-3.0Pre-tax Margin (%)28.8Higher ROA y-yN
Price/Book11.310-y EBITDA Growth Rate %--Quick Ratio2.5Cash flow > EarningsY
Price/Sales12.05-y EBITDA Growth Rate %--Current Ratio2.8Lower Leverage y-yN
Price/Free Cash Flow45.3y-y EBITDA Growth Rate %13.8ROA % (ttm)14.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)22.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)26.3Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

REGN is held by these investors:



REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Aberman Michael SSVP Strategy Investor Relation 2017-06-22Sell2,269$532.42-2.83view
STAHL NEILEVP Research and Development 2017-06-22Sell8,306$532.55-2.86view
GOLDSTEIN JOSEPH LDirector 2017-06-20Sell1,000$500.013.46view
BROWN MICHAEL SDirector 2017-06-20Sell3,000$5003.47view
Terifay Robert JEVP Commercial 2017-06-16Sell21,147$468.1910.5view
STAHL NEILEVP Research and Development 2017-06-15Sell8,567$468.4510.43view
BROWN MICHAEL SDirector 2017-06-12Sell2,000$474.459.04view
GOLDSTEIN JOSEPH LDirector 2017-06-09Sell1,000$482.557.21view
STAHL NEILEVP Research and Development 2017-06-02Sell2,812$479.497.89view
Sanofi10% Owner 2017-06-02Buy136,050$478.178.19view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885) Jun 22 2017 
Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United Sta Jun 21 2017 
Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (a Jun 11 2017 
Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (a Jun 11 2017 
Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at Am Jun 04 2017 
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at Am Jun 04 2017 
Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive P May 24 2017 
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately May 22 2017 
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately May 22 2017 
Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment i May 08 2017 

More From Other Websites
On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog Jun 23 2017
Sonic, Forestar post gains; BlackBerry, Regeneron fall Jun 23 2017
Week In Review: Biotechs, Software Drive Nasdaq; Boeing Tops Airbus; Oil Hit Jun 23 2017
Biotechs Hit Pause On 5-Day Rally As Regeneron, Bluebird Topple Jun 23 2017
Biotech Movers: Regeneron Slides Back After Big Gains Jun 23 2017
Regeneron (REGN) Stock on Fire: What's Behind the Surge? Jun 23 2017
After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Jun 22 2017
Why The Biotech Rally Could Still Tack On Another 15% Upside Jun 22 2017
If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Jun 22 2017
2 Key Stock Index Plays In Buy Range As Biotechs Surge Again Jun 22 2017
Health-Care Stocks Get a Boost From Senate Bill Rollout Jun 22 2017
Stock Indexes Grip Small Gains, But This New Leader Swings Higher Jun 22 2017
Regeneron: How High Can It Go? Jun 22 2017
Indivor's Opioid Use Disorder Drug Meets Primary Endpoint Jun 22 2017
Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885) Jun 22 2017
AveXis (AVXS) Jumps: Stock Rises 7.1% Jun 22 2017
Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4% Jun 22 2017
Futures: These 2 Big Breakouts Highlight New Market Leadership Jun 22 2017
Cramer finds where the real growth is in a split market Jun 21 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}